Pardes Biosciences, a developer of a COVID-19 pill named PBI-0451, plans to go public via a merger with blank check company FS Development Corp II (NASDAQ:FSDC), Reuters reports. A shareholder vote in this regard is scheduled for Thursday. Unlike the COVID-19 pill develope...
FS Development II (FSDC) has priced its upsized initial public offering of 17.5M Class A common stock (from 10M) at $10/share.Shares will begin trading today on Nasdaq.Offering is expected to close on February 19.Underwriters' over-allotment is an additional 2.625M shares.SPAC inetn...
Biotech stock Gemini Therapeutics (GMTX) fell nearly 8% on its opening day of Nasdaq trading Monday following a merger with a SPAC, but CEO Jason Meyenburg isn’t worried. “If there were some real event that were driving the company down a little bit in price today, I think [that...
Foresite Capital sponsored FS Development Corp. (FSDC) and precision medicine company Gemini Therapeutics have entered into a definitive merger agreement creating a new company focused on age-related macular degeneration.Current Gemini shareholders are converting 100% of their existing e...
A special purpose acquisition company (SPAC) is a publicly traded shell company that raises capital with the intent of acquiring a private business. SPACs have become an intriguing alternative for companies that want to go public because they allow that to happen much faster than with an init...
News, Short Squeeze, Breakout and More Instantly...
A special purpose acquisition company (SPAC) is a publicly traded shell company that raises capital with the intent of acquiring a private business. SPACs have become an intriguing alternative for companies that want to go public because they allow that to happen much faster than with an init...